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Abstract: Phocine distemper virus (PDV) was first recognized in 1988 following a massive 
epidemic in harbor and grey seals in north-western Europe. Since then, the epidemiology of 
infection in North Atlantic and Arctic pinnipeds has been investigated. In the western North 
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Atlantic endemic infection in harp and grey seals predates the European epidemic, with 
relatively small, localized mortality events occurring primarily in harbor seals. By contrast, 
PDV seems not to have become established in European harbor seals following the 1988 
epidemic and a second event of similar magnitude and extent occurred in 2002. PDV is a 
distinct species within the Morbillivirus genus with minor sequence variation between 
outbreaks over time. There is now mounting evidence of PDV-like viruses in the North 
Pacific/Western Arctic with serological and molecular evidence of infection in pinnipeds 
and sea otters. However, despite the absence of associated mortality in the region, there is 
concern that the virus may infect the large Pacific harbor seal and northern elephant seal 
populations or the endangered Hawaiian monk seals. Here, we review the current state of 
knowledge on PDV with particular focus on developments in diagnostics, pathogenesis, 
immune response, vaccine development, phylogenetics and modeling over the past 20 years. 
Keywords: Morbillivirus; pinnipeds; sea otter; CD150/SLAM; phylogeny; pathology; 
epidemiology; immunity; vaccine 
 
1. Introduction 
Beginning in late 1987 seemingly unprecedented epidemics spread through pinniped populations 
from Siberia to Western Europe. The series began with the mass mortality of Baikal seals (Pusa sibirica) 
in land-locked Lake Baikal [1]. The event followed an outbreak of canine distemper virus (CDV) 
infection in terrestrial mammals and a variety of diagnostic tests later confirmed that CDV was 
implicated in the seal deaths [1,2]. Shortly afterwards, beginning in April 1988, an epidemic swept 
through breeding colonies of European harbor seals (Phoca vitulina vitulina) around the coasts of the 
North, Baltic and Irish seas killing up to 18,000 of this species and possibly a few hundred sympatric 
grey seals, Halichoerus grypus [3]. However, while the clinical presentation and pathology were similar 
to CDV infection, antigenic characterization and gene sequencing demonstrated that the virus was a 
novel and distinct member of the Morbillivirus genus, phocine distemper virus, PDV [4–6].  
The course and outcome of the 1988 PDV epidemic suggested that this was a “virgin soil” event in 
previously naïve animals [7] and raised the question of where the virus had originated. Limited serology 
from archived sera of European seals collected prior to 1988 showed no prior evidence of  
infection [6,8,9]. An early hypothesis that harp seals (Pagophilus groenlandicus) from the eastern Arctic 
may have been the source of infection was supported by subsequent serological surveys in Norway, 
Greenland and Canada [10–14]. 
A symposium and round table discussion was convened in Hannover, Germany, in 1994 to review 
the current knowledge on marine mammal morbilliviruses [15,16]. Twenty years later, August 2014,  
a Research and Policy for Infectious Disease Dynamics (RAPIDD) workshop was convened on marine 
mammal morbilliviruses at Princeton University, USA, to discuss recent advances in research on PDV 
pathology, pathogenesis, transmission, species susceptibility, immunology and development of 
vaccination strategies for naïve threatened species such as Mediterranean (Monachus monachus) and 
Hawaiian (M. schauinslandii) monk seals, and future directions for research. As an outcome of the 
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workshop and round table discussion, we review the pertinent research in these relevant fields that has 
been published in the past 20 years and identify knowledge gaps requiring further research investment.  
2. Antigenic and Molecular Characteristics of PDV 
The Morbillivirus genus comprises well known pathogens of terrestrial mammals including measles 
virus (MV) a pathogen of humans and primates, rinderpest virus (RPV) and peste des petits ruminants 
(PPRV) both pathogens of ungulates and CDV a pathogen of carnivores [17]. A recently identified virus 
in cats has been proposed as a new morbillivirus of domestic felines, feline morbillivirus (FmoPV) [18]. 
Although this virus has the same gene organization as morbilliviruses, its pathological and molecular 
biological features are quite different from those of the conventional morbilliviruses. Among marine 
mammals, cetaceans (whales, dolphins and porpoises) may be infected by the recently recognized 
cetacean morbillivirus (CeMV) in which a number of strains are now recognized globally including 
dolphin morbillivirus (DMV), porpoise morbillivirus (PMV) and pilot whale morbillivirus  
(PWMV) [19–27]. Although not a subject of this review, CDV from terrestrial hosts has caused 
epidemics among land-locked Baikal seals and Caspian seals (P. caspica) since the late 1980s [1,28]. 
The morbillivirus genome is comprised of a non-segmented, negative-sense, single stranded RNA that 
varies from 15,500 to 16,050 nucleotides in length and contains six transcription units that encode six 
structural proteins: nucleocapsid (N), phosphoprotein (P), matrix (M) protein, fusion (F) glycoprotein, 
hemagglutinin (H) glycoprotein, and the major component of the RNA-dependent RNA polymerase,  
the large (L) protein. Two non-structural proteins (C and V) sometimes termed virulence factors that 
interfere with the innate immune response and affect infectivity, are also expressed in infected cells. 
Preliminary genetic characterization of PDV isolates from the 1988 epidemic using cDNA probes 
confirmed its membership in the Morbillivirus genus as a novel species [5,29–31]. Phylogenies of 
morbilli and paramyxoviruses based on partial [32–35], and more recently, complete gene  
sequences [36] consistently place all PDV strains as a monophyletic sister clade to CDV across all genes. 
Recent evidence points to bats as a potential source of significant paramyxovirus diversity, with some 
taxa clustering with the CDV/PDV group [37]. Host jumping appears to be relatively common in the 
Paramyxovirinae, and morbilli-like viruses are found in diverse mammals [38]. Final confirmation of 
the unique identity of PDV was achieved with full genome sequencing using a 1988 isolate in Vero cells 
expressing the canine receptor CD150 [39]. The genome was 15,696 nucleotides in length with the 
typical six non-overlapping morbillivirus genes in the order N-P/V/C-M-F-H-L [39]. Like all other 
morbilliviruses it obeys the rule of six [40].  
A second and equally devastating epidemic occurred among European harbor seals in 2002, with a 
similar temporal and geographic range to the 1988 event [41]. The similarities raised the possibility that 
the virus had persisted in the region in either marine or terrestrial hosts. Epitope mapping of five 
structural proteins from the 1988 and 2002 isolates using a panel of monoclonal antibodies found no 
differences between the PDV isolates, suggesting a high degree of antigenic conservation over the 14 
year time span [42]. However, phylogenetic analysis of the wild-type H genes from PDV 1988 and 2002 
showed distinct differences between isolates from each epidemic, suggesting that the virus circulating 
in 2002 had been reintroduced into the North Sea and not maintained in either marine or terrestrial hosts 
over the intervening interval [43]. Equally intriguing was the discovery that a PDV isolate from a harbor 
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seal stranded in Maine, USA in 2006 during an unusual mortality event was more similar to the 
Netherlands 1988 isolate than to the European 2002 isolates when compared using the H gene and 
deduced amino acid sequences [44]. The authors concluded that multiple lineages of PDV may be 
circulating in endemically infected seal populations in the eastern North Atlantic, a situation analogous 
to that of CDV in terrestrial carnivores [45]. Given the lifelong immunity and significant cross-protection 
seen between different morbillivirus strains, the maintenance of multiple strains in seal populations is 
surprising and further study into survival of strains between epizootics is merited [39]. 
 
Figure 1. Evolutionary relationships of phocine distemper virus (PDV) isolates to the other 
morbilliviruses. The neighbor-joining method [46] was used to generate a phylogenetic tree 
based on the hemagglutinin (H) glycoprotein sequences of seventeen selected PDV, CDV, 
MV, RPV, PPRV and DMV strains (branch length 1.59). Positions containing gaps were 
eliminated. Bootstrap analysis [47] was used to indicate the percentage number of trees from 
1000 replicates in which the virus H glycoprotein sequences clustered equivalently. Branch 
lengths are identical to the evolutionary distances, determined using the p-distance  
method [48], used to infer the phylogenetic tree. Sequence alignments and phylogenetic 
analysis was performed using MEGA5 [49]. PDV accession numbers (Z36979.1; 
AF479276.1; AF479277.1; AF479274.1; D10371.1; KC802221; AJ224707.1; HQ007902.1 
and FJ648456.1), PDV/2-RUS (1988) * (X84998.1) is generally accepted to be a CDV isolate 
although the name has not been changed. CDV accession numbers (HM046486.1, USA-RI 
and USA-R252, in submission). Other morbilliviruses, accession numbers, MV 
(HM439386.1), RPV (NC006296.2), PPRV (FJ750563.1) and DMV (FJ648457.1), were 
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included to show the evolutionary distances across the genus. Feline morbillivirus was not 
included in this analysis as it is questionable if this virus is a true morbillivirus. 
A phylogenetic tree was constructed de novo from published and unpublished H gene sequences of 
PDV (Europe 1988, 2002, USA 2006), CDV (R252 canine strain, a wild-type raccoon strain, Baikal seal 
CDV and Caspian seal CDV), RPV, MV and DMV (representing the cetacean morbilliviruses) to 
demonstrate the evolutionary relationships of PDV isolates within the wider genus (Figure 1).  
Neighbor-joining methodology was used and the H glycoprotein was chosen as this is under 
immunological pressure. Furthermore, it is known that there is good correlation between trees generated 
using H gene sequences and those using the highly variable cytoplasmic tail of the N protein, which is 
commonly used for morbillivirus genotyping [50]. The phylogenetic tree demonstrates that PDV and 
CDV cluster into distinct, but evolutionary similar, lineages and each lineage has several variants 
circulating as wild-type virus with slight variations between PDV isolates from the northeastern and 
northwestern Atlantic. 
3. Clinical Signs, Pathogenesis and Pathology  
3.1. Clinical Signs of Infection 
The clinical course of acute PDV infection in free-ranging pinnipeds has most frequently been 
observed in harbor seals, and occasionally grey, harp and hooded seals, during epidemics or mortality 
events in Europe and North America [51–57]. Signs may include pyrexia, serous or mucopurulent ocular 
and nasal discharges consistent with conjunctivitis, keratitis, ophthalmitis and rhinitis. Respiratory signs 
include coughing, mucosal cyanosis, dyspnea with interstitial and subcutaneous emphysema in severe 
cases increasing buoyancy and impeding normal swimming and diving. Females infected during 
pregnancy are prone to abortion. Moribund seals remain ashore for longer and may develop pressure 
necrosis and higher than expected ectoparasite burdens. Neurological signs manifest as depression, 
lethargy, head tremors, convulsions and seizures. Clinical infection has been described in one juvenile 
harp seal from eastern Canada that was moribund for one week with lethargy, severe conjunctivitis, 
multifocal epidermal ulceration, mucosal cyanosis and increased lung density on radiographs [53]. 
3.2. Pathogenesis, Cell Receptors and Tissue Tropism  
The morbillivirus H glycoprotein is required for attachment to a specific host cell membrane receptor 
while the F glycoprotein interacts specifically with H to facilitate viral envelope fusion with the host cell 
membrane [58]. The specific interaction of the viral H and F glycoproteins with the host cell receptor(s) 
determines host susceptibility, tissue tropism and viral pathogenesis. However, because morbilliviruses 
infect a number of different cell types in vivo including leucocytes, epithelial, endothelial and neural 
cells, more than one receptor type is required [59].  
The complement binding glycoprotein CD46 was first shown to be a competent receptor for MV, 
possibly with the involvement of a cytoskeletal protein, moesin [58,60]. A related glycoprotein CD150 
(or SLAM/F1, signaling lymphocyte activation molecule F1) was demonstrated using in vitro techniques 
to be a principal cellular receptor for MV, RPV and CDV in people, cattle and dogs respectively [61,62]. 
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Recently, expression of CD150 was confirmed on lymphocytes of a wide range of species in the 
suborders Caniformia and Feliformia including spotted seals (Phoca largha) and walrus (Odobenus 
rosmarus), while both CD150 and CD46 are expressed on harbor seal lymphocytes [63–65]. CD150 is 
a member of the C2 subset of the immunoglobulin superfamily and is expressed on activated B and T 
cells, constitutively on immature thymocytes, memory T cells, a proportion of B cells as well as activated 
monocytes and mature dendritic cells [66–68]. Phylogenetic research suggests that host CD150 and viral 
H glycoprotein have co-evolved [69]. Further work confirmed that CD150, but not CD46, is used by 
wild-type (wt) PDV as a host cell receptor [59]. Use of transfected Vero cell lines containing canine 
CD150 receptors allow for the efficient isolation of CDV, PDV and CeMV [44,70]. As there is a broad 
recognition of canine CD150 by a number of morbilliviruses it is hypothesized that cross-species 
infections are likely to occur in the future [71].  
In experimental studies using the ferret-CDV model, it was shown that the H protein is a key 
determinant of virus interaction with CD150, and that variations in this protein may influence tissue 
tropism [70,72,73]. Molecular evolution studies of CDV isolates from non-canine carnivores indicate 
that variation at a small number of key H protein residues involved in binding to CD150 may drive CDV 
adaptation to new hosts [74]. Although the H-protein sequence is overall not well conserved, two clusters 
of H amino acid residues involved in CD150 attachment (positions 526–529 and 547–548 and amino 
acid 552) are highly conserved and possibly facilitate overlapping host ranges between PDV and  
CDV [43,63,73]. 
A second mammalian cell surface receptor expressed mainly on the basal-lateral surfaces of epithelial 
cells, the poliovirus receptor-like protein 4 (PVRL4), also known as nectin 4, has been identified as a 
receptor for MV, CDV and PPRV [75–78]. This receptor is also up-regulated by MV in human brain 
endothelial cells [79]. Recently, PVRL4 was shown to be a receptor for wtPDV, potentially increasing 
the host range for the virus as it is a commonly expressed surface molecule on mammalian epithelial 
cells [59]. However, because of the ability of wtPDV to replicate in Vero cells without prior adaptation, 
it has been proposed that wtPDV may use other host cell molecules such as Toll-like receptors, interferon 
gamma (IFNγ), interleukin-4 (IL4), IL8, IL10, pro-HB-EGF and the vitamin A receptor (RARa) [59,65]. 
It has also been postulated that alternate mechanisms of infection must be used by morbilliviruses to 
enable infection of neural cells that do not express CD150 or PVRL4, and for intra-cerebral spread in 
subacute-sclerosing panencephalitis, SSPE, in people [80].  
Thus, the molecular biology and receptor usage of PDV would presumably parallel that of CDV and 
MV [77,81]. In laboratory studies, ferrets infected with CDV and macaques infected with MV show 
initial (5 to 6 days post infection) primary replication in lymph nodes and secondary lymphatic organs 
including those of the lungs, bronchi, and trachea [82–85]. Later (12 days post infection), most infected 
cells of the trachea are of lymphoid or myeloid origin and are located beneath the epithelium. CDV uses 
CD150 as a receptor to infect lymphocytes and dendritic cells and presumably uses PVRL4 to infect 
epithelial cells in the respiratory tract and elsewhere in the body where this receptor is expressed on 
epithelia. The logistical difficulty of working with pinniped species when experimental infections are 
impossible, may require the use of in vitro models. These could be used to identify differences in virus 
attachment to peripheral blood lymphocytes from harbor, grey and harp seals [86]. 
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3.3. Gross Pathology  
Based on experimental infectivity studies, the pathogenesis and pathology of PDV infection in harbor 
seals is similar to that of CDV in dogs [87,88]. Initial viral replication appears to occur in lymphoid cells 
with secondary dissemination to epithelial and endothelial cells in various organ systems and to the 
central nervous system [83,87,89]. Histopathology and the immunohistochemical localization of 
morbillivirus antigen, such as N protein, in tissues of naturally-infected harbor, grey and harp seals have 
been described in detail and extensively reviewed [53,90–94]. In summary, pneumonia is the principal 
gross lesion with variable consolidation, atelectasis, congestion, edema and emphysema. The latter is 
rarely limited to the lungs with combinations of interlobular, sub-pleural, mediastinal, pericardial, 
retroperitoneal and subcutaneous emphysema. Bronchial and mediastinal lymphadenopathy are 
frequent. Primary PDV pneumonia is often complicated by concurrent parasitic pneumonia 
(Parafilaroides spp.), bacterial infections (Bordetella bronchiseptica, Streptococcus spp. Clostridium 
spp. among others) and viral co-infections (Phocid herpesvirus 1, Influenza A virus). Consequently there 
may be suppurative and hemorrhagic pneumonia, mucopurulent exudates in airways, pleuritis, 
hematomas and infarction. Dermatitis is often manifested as focal or locally extensive areas of 
hyperkertosis on ears, eyelids and foot pads of terrestrial carnivores infected by CDV [95]. Similar 
pathology has not been reported for harbor seals, the pinniped most susceptible to PDV. However, focal 
crusting on the dorsal surface of the flippers, head, trunk and tail was described for a juvenile harp seal 
and hooded seal (Cystophora cristata) stranded on the US Atlantic coast [55]. 
3.4. Histopathology  
Characteristic histopathologic lesions of PDV may be observed in the respiratory tract, lymphoid 
system, various epithelia and the central nervous system [51,53,54,90,91,94,96]. Bronchointerstitial 
pneumonia is characterized, in cases uncomplicated by secondary infections, by serofibrinous alveolar 
exudates containing leukocytes and macrophages. Serofibrinous exudate is replaced in subacute cases 
by hyaline membranes and in more chronic cases, fibroplasia in alveolar septa and infiltration by 
lymphocytes, plasma cells and other leukocytes. Initial viral replication in type I pneumocytes during 
acute infection results in their necrosis and eventual replacement by type II pneumocytes in more  
sub-acute cases. Syncytia are found in bronchioles, alveoli and peri-bronchiolar glands but these are 
generally less numerous and smaller than the equivalent in cetaceans infected by CeMV [93]. 
Acidophilic intracytoplasmic inclusion bodies (ICIB) and intranuclear inclusion bodies (INIB) of 
respiratory epithelium have been observed throughout the tract including bronchiolar gland epithelium, 
type II pneumocytes and in syncytia. Inclusions are generally discrete, ovoid (10–20 µm) with distinct 
borders. Similar inclusions may be present in transitional epithelium of the renal pelvis and urinary 
bladder, biliary and pancreatic ducts, tonsils and gastro-intestinal epithelia, and conjunctiva.  
Marked necrosis and depletion of lymphocytes in spleen, thymus, gut-associated lymphoid tissue and 
peripheral lymph nodes is characteristic. Acidophilic ICIBs may be observed in lymphoid tissues and 
severely depleted follicles may have central syncytia. Non-suppurative encephalitis in harbor and harp 
seals is remarkably similar to those of spontaneous CDV in dogs [97,98]. The distribution is generally 
cerebral and often with a laminar or multifocal pattern of neuronal and glial necrosis in the cerebral 
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cortex, mononuclear perivascular cuffing, astrocytosis, microgliosis, neuronophagia and focal 
demyelination in cerebral white matter. Acidophilic ICIBs and INIBs are frequently seen in neurons and 
astrocytes (Figure 2). In dogs, an acute and chronic or relapsing manifestation of demyelinating CDV 
infection has been described [98]. The acute phase occurs around three weeks post infection and 
coincides with the period of viral-induced immunosuppression [99]. These animals may progress to 
death, recover after mild or subclinical illness, or develop a chronic or relapsing disease with persistence 
of the virus in the brain and progression of demyelination mediated by immunopathological  
mechanisms [98,100]. While it is plausible that this may also occur in pinnipeds with PDV infection, it 
has not been demonstrated. Neither is there evidence for an old dog encephalitis (ODE)-like syndrome 
in pinnipeds. ODE is an extremely rare condition in dogs manifesting as neurological deficits years after 
primary CDV infection. It is characterized by an intense inflammatory reaction in the forebrain (frontal 
cortex, basal nucleus, pyriform lobe, rostral thalamus, and rostral subcortical white matter) with sparing 
of the hindbrain (cerebellum and caudal brain stem) and occipital cortex (grey and white matter). 
Histologically, there are prominent perivascular cuffs, neuronal necrosis, astrocytosis, formation of 
multinucleated giant cells and focal demyelination with ICIBs in astrocytes and giant cells [101]. 
PDV–associated dermatitis has been documented in a harp and hooded seal characterized by a focally 
thickened epidermis with three distinct layers: a deeply eosinophilic superficial layer of orthokeratotic 
hyperkeratosis, a zone of hyperplastic basal cells, and middle band with numerous necrotic syncytial 
cells some of which with as many as 30 to 40 nuclei. These areas resembled syncytial zones rather than 
discrete syncytial cells. Hair follicle infundibula had similar changes. Eosinophilic ICIBs were observed 
in epidermal, follicular and sebaceous cells but INIBs were rare. Syncytia were also present in sebaceous 
glands [55]. 
3.5. Age-Specific Pathology 
The high mortality resulting from the 2002 PDV epidemic in Europe enabled a detailed pathological 
assessment of 369 harbor seal stranded on the coasts of The Netherlands [94]. The seals were aged based 
on dentin layers in teeth and classed as <1, 1 to 2 years, and 3 years or older. Analysis of the pathology 
and ancillary diagnostic results enabled insights into the distribution of lesions, temporal presence of 
viral antigen or genome in organs, and influence of co-infections. The data confirmed the differential 
temporal occurrence of PDV in lung and brain. As in dogs with CDV, PDV virus persisted much longer 
in the brain than in lung. As in the 1988 epidemic, a greater proportion of older animals had PDV 
neutralizing antibodies. This study supported the hypothesis that there was greater mortality among 
younger age classes and age-related immune compromise in younger seals. The course of disease in 
older seals may also be longer enabling the development of an immune response. A second age-related 
observation was the development and severity of extra-thoracic emphysema that increased with age and 
was possibly related to the more chronic course of disease in older animals or their diving behavior. The 
study further enabled documentation of the role of PDV-induced immunosuppression in the promotion 
of secondary bacterial and parasitic infections in older animals.  
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Figure 2. (A) Grey seal (Halichoerus grypus) cerebrum showing expanded Virchow Robin 
space containing lymphocytes. Activated endothelial cell (arrow). H&E stain (B) Grey seal 
cerebrum with marked non-suppurative meningoencephalitis. H&E stain (C) Grey seal 
cerebral white matter with focal malacia centrally and peripheral focal hemorrhage. H&E 
stain (D) Grey seal cerebrum with acidophilic intranuclear inclusion bodies (INIB, arrow) 
and intracytoplasmic inclusion bodies (ICIB, arrow heads). H&E stain (E) Grey seal 
hippocampus with acute focal neuronal necrosis. H&E stain (F) Harp seal (Pagophilus 
groenlandicus) cerebrum with numerous INIBs (arrows). H&E stain; (G) Harp seal 
cerebrum showing laminar distribution of morbillivirus antigen. Immunohistochemistry 
(IHC) using primary antibody against the nucleocapsid (N) of canine distemper virus 
(VMRD, Inc., Pullman, WA, USA); (H) Harp seal cerebrum. Neurons with strong staining 
of morbillivirus antigen in cytoplasm and nuclei (arrows). IHC stain as described. The grey 
seal tissues are from a pup that stranded in February 2006 in Maine, USA, with neurological 
clinical signs [56]. The harp seal tissue is from a juvenile that stranded on Prince Edward 
Island, Canada, in May 1991 with similar clinical signs [53]. 
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4. Diagnosis 
The clinical signs of respiratory tract infection seen in seals with PDV and the associated oculo-nasal 
discharge and conjunctivitis are nonspecific and may be seen with Influenza A virus and other  
infections [102,103]. Similarly, the neurological impairment is similar to that seen following ingestion 
of marine algal biotoxins such as domoic acid [104]. Gross pathology in cases of acute respiratory 
infection is highly suggestive of PDV but not pathognomonic. Serology is most useful for population 
surveillance and less so as a diagnostic tool for individual animals. Antigen-capture enzyme-linked 
immunosorbent assays (ELISA) have been used on tissue homogenates [105]. Histopathology, 
immunohistochemistry and molecular diagnostic techniques as described below are currently the most 
commonly used laboratory tests for confirmation of infection.  
4.1. Serology 
Because serological tests do not always measure the same analyte (e.g., IgM versus IgG, antibodies 
directed against different viral antigens), results from different tests are not always comparable.  
Virus neutralization (VN), and plaque reduction (PR) tests are the most extensively used to determine 
the presence of antibodies against morbilliviruses in the blood of a large number of pinniped  
species [6,10,12,106–108]. These are also the only available serological tests that can different between 
CDV and PDV infections in which a differential antibody titer of 4-fold or greater indicates homologous 
as opposed to heterologous exposure. While both tests are capable of detecting circulating antibodies, 
PR testing has the added advantage in that it can be used on the more degraded or hemolysed and whole 
blood samples usually obtained from beached carcasses or from animals harvested for food by 
indigenous hunters. Testing is usually done for both assays using standard Vero cells. However, use of 
Vero.DogSLAMtag cells, expressing canine CD150 receptor, which are more sensitive to virus growth, 
permits reduction of testing time by 1–2 days for both the VN and PRN tests, [109], Saliki, unpublished 
observations]. CDV, PDV and CeMV all share numerous antigenic determinants that are recognized by 
infected hosts. It has been shown that serum antibodies raised against one morbillivirus will neutralize 
the homologous virus to a higher titer than the heterologous morbilliviruses [12,108,110]. This allows 
the determination of the species of morbillivirus responsible for infection and greatly increases our 
knowledge regarding the epidemiology and transmission of specific viruses in free-living populations 
worldwide [12,106,111].  
4.2. Histopathology and Immunohistochemistry 
The identification of acidophilic or amphophilic ICIBs or INIBs in hematoxylin and eosin (H&E) 
stained tissue sections is strongly suggestive of morbillivirus infection. When dealing with potentially 
new host species, or new areas of disease emergence, it is recommended to use ancillary tests such as 
immunohistochemistry to confirm the presence of morbilliviral antigen [51,53,54,97]. 
Immunohistochemistry is also extremely useful if the classic histological lesions or inclusions are no 
longer visible or equivocal as can occur in more chronic cases and in animals where the viral lesions are 
masked by severe inflammation or necrosis caused by secondary infections. Currently, most laboratories 
use an avidin-biotin complex (ABC) technique and either a primary monoclonal antibody against the 
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nucleocapsid (N) of CDV (VMRD, Inc., Pullman, WA, USA) or polyclonal rabbit anti-CDV 
nucleoprotein [112,113].  
4.3. Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
By far the most common PCR assay used for detection of PDV is the “universal” morbillivirus primer 
set that amplifies a 486 bp fragment of the P gene, followed by nested PCR using specific primer sets 
that amplify a 384 bp fragment of the PDV and CDV P genes respectively, to ascertain which virus is 
present [114,115]. This assay has been used to detect PDV in live animals (whole blood, nasal, 
pharyngeal or ocular swabs) and in tissues such as trachea-bronchial lymph nodes, spleen, liver, kidney, 
lung and brain from carcasses. This assay was used to test tissue samples from the 2002 European harbor 
seal epidemic [116] and more recently from nasal swabs and archived tissues from Northern sea otters 
(Enhydra lutris kenyoni) in Alaska [117]. Stanton et al. [113] modified the P gene primers to shorten the 
amplicon to a 149 bp fragment for use in formalin-fixed paraffin-embedded tissues. The assay 
maintained the sensitivity to differentiate CDV and PDV, and was useful for determining that CDV was 
present in formalin-fixed paraffin-embedded tissues from a Caspian seal; and PDV in harp, hooded and 
European harbor seal tissues. A quantitative real-time PCR assay was used during the North Sea 
European harbor seal epidemic in 2002 to test samples from sympatric grey seals for evidence of PDV 
infection shortly after the peak of the epidemic [118]. The TaqMan probe and primers were designed 
using the PDV H gene sequence from the 1988 epidemic (GenBank accession no. D10371). Primers 
were also designed to amplify a fragment of the grey seal b-actin gene, as a housekeeping gene to 
determine the integrity of the cDNA and to confirm PCR efficiency of the assay. Incorporation of the  
b-actin assay is useful for better interpretation of negative results when using any of the morbillivirus 
assays. Real-time PCR was chosen over conventional RT-PCR as it allowed for both detection and 
quantification of the number virus copies in the sample. More recently, Earle et al. [44] designed 
additional PDV primers to amplify the H, F, M, and P genes using previously published PDV sequences, 
for confirmation of the USA 2006 PDV outbreak in harbor seals. Selected fragments of the PCR products 
are then sequenced for virus identification and phylogenetic analysis. 
Recently, a one-step duplex quantitative RT-PCR assay (RT-qPCR) based on TaqMan probe technology 
was developed to quantify PDV along with the glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) 
gene to simultaneously assess RNA quality [119]. This approach will be useful to reduce the likelihood 
of false negative diagnosis in degraded field samples. Another recent development is a pan-marine 
mammal morbillivirus semi-nested RT-PCR using a degenerate set of primers targeting conserved 
sequences of the P protein has been described [120], which detects both pinniped and cetacean 
morbilliviruses. Such an assay is useful for detecting morbilliviruses in multiple marine mammal species. 
4.4. Virus Isolation 
Morbilliviruses are notoriously difficult to isolate and propagate in cell culture [121]. PDV was first 
isolated by experimentally infecting dogs with spleen, lung, and lymph node homogenate from three 
naturally-infected infected seals [6]. The first direct isolation was from a primary kidney cell culture 
from a naturally-infected harbor seal [122]. Co-cultivation of buffy coat leukocytes from infected seals 
with Vero cells has also been successful [123]. More recently, Vero cells expressing the dog CD150 
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receptor were tested in order to develop a cell culture and isolation methodology that may be more useful 
for isolating and better understanding the phylogeny and evolution of marine mammal morbilliviruses [109]. 
Result showed that PDV replication in Vero.DogSLAMtag cells progressed rapidly (on the order of 
days) and required fewer passages, whereas virus replication in primary seal kidney and Vero cells took 
much longer (on the order of weeks) and required multiple passages [109]. Thus, these VeroSLAM cells 
are now used routinely for isolation of marine mammal morbilliviruses, including PDV.  
5. Immunology, Species Susceptibility and Vaccination 
5.1. Immune Response to PDV  
Based on natural and experimental infection, harbor seals appear more susceptible to PDV than grey 
seals [51,124]. Species susceptibility may be due to multiple factors and include host-specific factors 
such as cell receptors and differences in immune response such as antigen processing and presentation, 
or cytokine production. Serologic surveys in Europe during and after the first PDV epidemic showed 
higher seroconversion rates in grey seals [125,126]. Harbor seals that died from PDV infection rarely 
had antibodies directed against the important F and H glycoproteins but had antibodies directed towards 
internal N and P glycoproteins of PDV and CDV and in this regard were similar to dogs that developed 
clinical CDV [30,127,128]. Further studies based on the precipitation of radiolabelled CDV proteins by 
sera from naturally infected grey and harbor seals from North America confirmed that grey seal sera 
strongly precipitated N protein and the H and F glycoproteins [129]. By contrast, significantly fewer 
harbor seal sera precipitated the envelope glycoproteins and responses were weaker than with grey seal 
serum. Harbor seals that died from PDV encephalitis or pneumonia precipitated the N protein alone or 
reacted weakly with the envelope glycoproteins [129].  
Similar studies on sera from clinically normal seropositive Canadian harp and hooded seals showed 
that harp seal sera reacted similarly to that of grey seals [12]. Significantly more harp seal sera (18 of 
20) precipitated N, F and H glycoproteins that those of hooded seals (7 of 20) while three seropositive 
ringed seal (Pusa hispida) sera precipitated N and F [12]. Thus, species differences in humoral immune 
response may be an important determinant in PDV susceptibility.  
Differential mortality within the European harbor seal metapopulation during the 1988 and 2002 
epidemics prompted studies of genetic population structure, genome wide genetic variation and variation 
in immune response genes [65,130–132]. Using microsatellite loci Goodman [130] demonstrated that 
despite their potential mobility, harbor seal populations in the European epizootic area showed strong 
genetic structuring. This would allow for differential distribution between populations of alleles 
contributing to susceptibility at functional loci, but overall levels of genetic variation were similar in 
populations experiencing high and low mortality. Recently fine scale population structure was identified 
over short geographic distances within Scandinavian populations [133]. Further examination of genetic 
variation using microsatellites and single nucleotide polymorphisms (SNPs) in the Wadden Sea harbor 
seal population (which showed high PDV mortality in both epidemics) demonstrated a link between 
individual levels of inbreeding and lungworm infection [132,134]. Whether individual inbreeding is 
relevant to PDV mortality remains to be tested, but the latter studies do establish a link between 
individual genetic variation and the response to an infectious disease in harbor seals. 
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Initial characterization of locus complement and variation of major histocompatibility (MHC) class I 
genes in eight harbor and four grey seals, found that both species had two expressed MHC class I lineages 
comprising one classical polymorphic lineage, a second non-classical non-polymorphic class I gene, 
plus a non-expressed pseudogene [131]. The highly polymorphic lineage showed the typical pattern of 
diversity for MHC genes consistent with diversifying pathogen driven selection, but higher levels of 
variation in grey seals (with 12 genes, 26 allotypes, 1–4 allotypes per locus) compared to harbor seals 
(with 6 genes, 18 allotypes, 1–4 allotypes per locus). It is still to be determined whether variation at 
MHC loci contributed to intra and interspecies differences in susceptibility to PDV at a population level. 
Nevertheless, the findings complement the previous studies on humoral immune response suggesting a 
greater capacity to respond to and neutralize PDV by grey seals than harbor seals [30,129]. 
Variation at targeted candidate immune genes was assessed in a sample of seals that either died from 
infection or survived and from several geographic locations [65]. The selected genes included 
morbillivirus receptors (SLAM and CD46), proteins involved in immune detection (TLR2), immune 
regulation (IFNG, IL4, IL8, IL10) and proteins involved in disease physiology (RARa, vitamin A 
receptor). No variation was found across Europe in protein coding domains for SLAM or CD46, but 
SNPs were found in SLAM intron 2, and exon 1 of IL8 and RARa. The available sample sizes did not 
have sufficient power to resolve a significant association with disease status, but consistent with the 
microsatellite data, there was significant differentiation of allele frequencies at the SNP loci among 
populations. This was a first attempt to investigate the association between genetics and disease 
susceptibility for wildlife using samples from an actual morbillivirus epidemic. Future studies 
incorporating full genome sequencing of the host species should enable a more refined analysis of the 
role of host genetics in the immune response and disease susceptibility [65,135]. 
The immunosuppressive effects of CDV on canine lymphocytes was demonstrated in vitro forty years 
ago [127]. More recent studies have shown that pro-inflammatory cytokines (IL-1β, IL-6, IL-12 and 
TNFα) are dominant in early infection in dogs [136,137]. As infection spreads, the response switches to 
an anti-inflammatory Th2 profile (IL-4, IL-10 and TGFβ) [138–140]. An in vitro study using mitogen 
stimulated and un-stimulated harbor seal lymphocytes demonstrated a very similar pattern as seen in 
dogs with switching to a Th2 response occurring between 24 h and 48 h post infection [141]. Assuming 
these results reflect natural morbillivirus infection, it is a plausible mechanism for the profound 
generalized immunosuppression seen in PDV infected seals.  
5.2. Vaccines and Vaccination Strategies for Free-Living Pinnipeds: Hawaiian Monk Seal Case Study 
Vaccination of free living wildlife has rarely been performed to protect the target population from 
infectious disease, with the notable exception of extensive vaccination of some vectors of zoonoses, such 
as rabies vaccination of raccoons in the eastern U.S or foxes in Europe. When vaccinating wildlife, 
vaccines must be selected that can be feasibly given to wildlife effectively, that confer a suitable duration 
of immunity for the species and disease of concern, and that do not disrupt disease surveillance in the 
target population. Marine mammals have been vaccinated when in rehabilitation settings to protect them 
from disease during care or after release [142,143], but vaccination of free living marine mammals is 
logistically difficult due to their aquatic life. In general, the use of attenuated live morbillivirus vaccines 
is contraindicated because of the potential risk of disease to the vaccinated animal, and potential for 
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spread to in-contact animals [144,145]. However, during the 1988 PDV epidemic commercially 
available attenuated CDV vaccine was successfully used to immunize harbor and grey seals and 
vaccinated pregnant grey seals transferred antibodies to their pups [125,142]. Experimental inactivated 
and subunit CDV vaccines were also used with mixed success in rehabilitated harbor seals [123,143,146]. 
To date, vaccination has not been used on free living marine mammals. The prospect of doing so is 
fraught with challenges not least of which is the administration of a vaccine by injection. If an inactivated 
vaccine is used, then a second booster shot may be required to achieve an adequate level of protection. 
Nevertheless, the challenge may be justified when highly endangered species such as the Mediterranean 
monk seal [147] or the Hawaiian monk seal are considered at risk. 
The Hawaiian monk seal is among the rarest of pinnipeds, with approximately 1200 individuals 
remaining throughout the Hawaiian Archipelago [148]. Currently, infectious disease is not known to be 
limiting monk seal recovery, and serology and post mortem results indicate that the population is naïve 
to PDV [149]. However, the species has extremely low genetic diversity [150], and although their 
susceptibility to morbilliviruses is unknown, DMV and CDV have been reported in cetaceans and 
domestic dogs in the Hawaiian Islands [25] and vagrant pinnipeds from the eastern North Pacific, where 
PDV has recently been reported [117], have been observed on Hawaiian beaches.  
Considering the devastating effects these viruses can have on phocid populations, the Hawaiian monk 
seal’s low abundance, low genetic diversity, and the potential for exposure to PDV and other 
morbilliviruses, planning is underway to prevent or mitigate a potential epidemic using disease 
surveillance (serology and necropsy) coupled with vaccination.  
The vaccination plan incorporates three elements: vaccine selection, captive animal testing for safety 
and efficacy, and vaccination of free-ranging seals. To date, the first two elements have been completed. 
The candidate vaccine is recombinant CDV (monovalent recombinant canary pox vector expressing CDV 
antigens, Purevax, Merial) licensed for use in ferrets in the U.S. and used in zoological collections [151]. It 
is the only CDV vaccine recommended by the American Association of Zoological Veterinarians 
(http://www.aazv.org) for use in wild carnivores and it is approved generically for use in Hawaii. 
Availability of this vaccine is a limitation to its use, as the product has been on manufacturer backorder 
for two years. Without greater certainty regarding the vaccine's future availability, development and 
testing of a new vaccine will be required, which may delay implementation of the vaccination plan. 
Safety and efficacy trials conducted on captive harbor and Hawaiian monk seals demonstrated no 
adverse reactions and no shedding of canary pox [152]. All subjects developed positive CDV (though 
not PDV) titers after receiving a booster approximately one month following initial vaccination. The 
vaccine has also proven to be a safe and effective prophylactic treatment for captive southern sea otters 
(E. lutra nereis) [153]. 
The optimal strategy for vaccinating free-ranging Hawaiian monk seals is currently under 
investigation. Low population abundance, one of the risk factors for an outbreak, also makes vaccinating 
a significant portion of the population tractable. Monk seals tend to haul out singly or as small groups 
on the beach, are individually identifiable, and are readily approachable. Thus, vaccine may be 
administered either by brief capture and physical restraint or using a pole syringe.  
It has yet to be resolved whether to: (1) vaccinate only in response to an outbreak; (2) conduct 
prophylactic vaccination; or (3) combine both approaches. Hawaiian monk seals are distributed in a 
metapopulation comprising many subpopulations spanning the 2500 km-wide archipelago [154]. Most 
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of the population resides in the remote Northwestern Hawaiian Islands (NWHI), associated with small 
islands and atolls, all but one of which are reachable only by boat. In contrast, a smaller but growing 
population occurs in the main Hawaiian Islands (MHI), home also to over one million people [155]. 
Because of the remote location, monk seals in the NWHI are monitored for at most a few months during 
summer. As such, detecting an outbreak in the NWHI could be delayed or completely escape detection. 
Thus, response vaccination is not a viable option. By contrast, monk seals in the MHI are monitored 
year round by volunteer observers and the general public. An outbreak of disease here would likely be 
reported so response vaccination may be a viable control option. 
Currently, a SEIR (Susceptible, Exposed, Infectious, Recovered) compartmental model is under 
development to simulate trajectories of morbillivirus outbreaks in MHI seals. Contact rates will be 
estimated using social network analysis of individual association data, and a plausible range of other key 
parameters (such as latency, duration of infectious period, etc.) will be extrapolated from other species 
and outbreaks. Efficacy of response vaccination in the face of a morbillivirus outbreak in the MHI will 
be evaluated. A key question is whether an adequate response can be mounted to immunize a sufficient 
portion of the population in time to halt transmission. With regard to a prophylaxis, the proportion of 
each subpopulation that must be vaccinated in order to achieve herd immunity will be estimated, along 
with the uncertainty surrounding these estimates. 
6. Epidemiology  
6.1. Transmission and Persistence 
In general morbilliviruses are transmitted horizontally by the respiratory route or by contact with oral, 
respiratory, and ocular fluids and exudates containing the virus [95,156]. Close contact between affected 
and susceptible animals is probably required due to the relative fragility of enveloped PDV in the 
external environment. For the same reason, transmission by fomites is probably not common. The highly 
aggregated nature of seal haul out sites would certainly predispose them to aerosolized virus from 
infected conspecifics [157]. Depending on the species, seals aggregate seasonally for breeding and 
molting which would also favor transmission of a highly infectious respiratory virus. It is noteworthy 
that epidemics or outbreaks of PDV among harbor seals in both Europe and New England began in 
spring during the pupping/breeding season or at winter haulout sites [41,44,54,158]. Other modes of 
horizontal transmission are also possible based on the distribution of PDV antigen in epithelia of the 
urinary tract and skin but these are probably relatively unimportant [51,53,55,88]. Transplacental 
transmission of morbilliviruses has been documented in dogs and is likely in cetaceans [159–161]. 
However, while abortion and stillbirth were features of the harbor seal 1988 and 2002 epidemics, vertical 
transmission has not yet been documented in pinnipeds.  
For horizontally-transmitted, highly-immunogenic infectious agents like morbilliviruses, there is 
generally thought to be a critical community size below which infection cannot persist without continued 
introduction of individuals with productive viral infection [162]. The number of susceptibles, the latent 
and infectious periods are also critical factors [163]. For MV, models predicted a threshold of at least 
250,000 to 500,000 people in a randomly mixing population [164–166] while an age-structured model 
for harbor seals in western Europe predicted a requirement for a population of 300,000 [167]. However, 
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CDV can persist among low-density populations of terrestrial carnivores that have a patchy distribution, 
live in small social groups, and tend to be territorial. Under these conditions continued transmission of 
the virus probably requires large spatial scales or multi-host transmission for persistence as has been 
described for wolves, coyotes and cougars in the Greater Yellowstone Ecosystem [168]. In this system 
recurring CDV-associated multi-host mortality events are a feature of the disease ecology [168,169].  
A parallel scenario of continued transmission, viral persistence and repeated disease outbreaks appears to be 
occurring among the phocid seal (harp, hooded, ringed, grey and harbor) of the northwestern Atlantic [170]. 
6.2. Global Distribution of PDV  
The emergence of PDV as an agent of mass mortality in 1988 changed our perception of the role of 
infectious diseases in marine mammal ecology and population dynamics. Indeed, following the first 
epidemic, Harwood and Hall [157] posited that such stochastic events likely play a more important role 
in population dynamics than density dependent factors. Certainly the magnitude of PDV on harbor seals 
in western Europe is reminiscent of the impact that other morbilliviruses, RPV and MV, had on 
previously naïve populations [171–173]. Ascertaining the role of endemic morbillivirus infection in 
regulating marine mammal populations in the western North Atlantic, and the potential for affecting 
long-term population persistence, particularly of harbor seals, in the eastern North Atlantic is more 
problematic. The recent emergence of a PDV-like virus in the North Pacific in previously naïve host 
species, but without large-scale mortality has further complicated an already complex epidemiology 
(Table 1). 
Table 1. Marine Mammals in which PDV has been detected. 
Ocean Province Species Pathology Serology PCR Reference 
Eastern North Atlantic Phoca vitulina Yes Yes Yes 
[4–6,28,29,51,91, 
92,94,96,174] 
(Inc. North, Baltic and Irish Seas) Halichoerus grypus No Yes No 
[28,90,92,125,126,
142] 
Arctic Cystophora cristata No Yes No [11] 
(Inc. Greenland, Barents, White and 
Norwegian Seas) 
Pagophilus groenlandicus No Yes No [10,11,14] 
 Pusa hispida No Yes No [14] 
Western North Atlantic Phoca vitulina Yes Yes Yes [49,106,175] 
(Eastern Canadian Arctic to Caribbean) Halichoerus grypus Yes Yes Yes [13,56,106,175] 
 Pagophilus groenlandicus Yes Yes Yes [11,12,53,55] 
 Cystophora cristata Yes Yes Yes [11,12,56] 
 Pusa hispida No Yes No [11,12] 
 
Odobenus rosmarus 
rosmarus 
No Yes No [107,176] 
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Table 1. Cont. 
Ocean Province Species Pathology Serology PCR Reference 
Eastern North Pacific and Bering Sea Phoca vitulina richardsii No No No [6,106,177–179] 
 Pusa hispida No No No [6] 
 Phoca largha No No No [6] 
 Histriophoca fasciata No No No [6] 
 Erignathus barbatus No No No [6] 
 
Odobenus rosmarus 
divergens 
No No No [6] 
 Eumetopias jubatus No No No [6,180] 
 Callorhinus ursinus No No No Gulland unpublished 
 Enhydra lutris kenyoni No Yes Yes [117,179,181,182] 
 Enhydra lutris nereis No No No [179] 
 Zalophus californianus No No No Gulland unpublished 
 Arctocephalus townsendi No No No Gulland unpublished 
Western North Pacific Phoca vitulina stejnegeri No Yes No [183,184] 
(Sea of Okhotsk, Sea of Japan,  
Yellow Sea) 
Eumetopias jubatus No Yes No [184] 
 Phoca largha No Yes No [184] 
Southern Oceans      
New Zealand Phocarctos hookeri No Yes No [185,186] 
 Arctocephalus forsteri No Yes No [185,186] 
Australia 
Arctocephalus pusillus 
doriferus 
No No * No [187] 
Antarctica Lobodon carcinophagus No No No [111,188]# 
 Hydrurga leptonyx No No No [188] 
 Leptonychotes weddellii No No No [111,188] 
 Ommatophoca rossii No No No [111] 
* Sera tested against Lederle strain CDV in plaque reduction SNT on VeroDogSLAMtag cells; # CDV serology only. 
6.2.1. Western North Atlantic 
Retrospective studies indicate that PDV has been circulating among several phocid seal  
species, the Atlantic walrus and polar bears in the western North Atlantic since at least the  
1970s [12,13,106,107,125,158,175,176,189]. The highly gregarious and seasonally aggregated harp  
seal [190] appears to be a key species in the disease ecology of PDV in this ecosystem, with a population 
size well above estimates required to maintain endemic infection [167]. The historical, pre-European 
colonization, estimates suggest that there were at least eleven million animals in Canadian waters with 
only a moderate decrease to eight million in 2011 [191]. Breeding age females sampled in the Gulf of 
St. Lawrence between 1988 and 1993 were shown to have 83% PDV seropositivity, consistent with 
endemic infection [12]. This high level of herd immunity precludes large-scale mortality in a population 
in which most pups will have maternal antibody and susceptibility limited to a short window when 
maternal immunity wanes and acquired immunity provides life long protection. In keeping with this, the 
only confirmed PDV mortality among harp seals has been in juveniles dispersing away from the breeding 
colonies in spring [53,55]. 
In the eastern Canadian Arctic it was found that the prevalence of PDV antibody in ringed seals was 
significantly higher where they were sympatric with migratory harp seals [12]. It is also likely that harp 
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seals act as a reservoir of infection for the less gregarious hooded seals, with whom they share whelping 
patches on the sea ice in March, and the relatively small Atlantic walrus population, with whom they are 
also seasonally sympatric [12,107,176]. From late winter though early summer, harp seals are also 
sympatric with both grey and harbor seals in the Gulf of St. Lawrence, Maritime Canada and along the 
New England coast. As with harp seals, high levels of seropositivity (73%) were found in adult grey 
seals sampled in eastern Canada between 1980 and 1994 [106]. Furthermore, as with harp seals, grey 
seals are a highly gregarious species aggregating in huge numbers for the winter (January-February) 
breeding season and early spring molt, and wide dispersal of pups of the year [192–195]. Like the harp 
seal, the grey seal population in eastern Canadian waters is large and expanding with growth by an 
estimated 975% between 1977 and 2010 to approximately 348,900 animals [196]. The New England 
grey seal population has greatly expanded with establishment of breeding colonies in Maine and 
Massachusetts [193,197]. By contrast, the PDV antibody prevalence in harbor seals in this region over 
the same period was only 37% [106], but still much higher than in European harbor seals (11%) in  
post-epidemic years [198]. It was suggested that the smaller population size of this species in eastern 
Canada and Atlantic USA, its more fragmented distribution, and less gregarious behavior would not be 
sufficient to maintain endemic infection without contact with either grey or harp seals [106]. 
Furthermore, the lower level of herd immunity in harbor seals would leave them vulnerable to periodic 
mortality events. This indeed appears to be the case with a confirmed PDV mortality event occurring 
along the Atlantic coast from eastern Canada to Long Island, New York, over the winter of 1991/’92 
that was preceded by mortality in juvenile harp seals in eastern Canada in spring 1991 [53,54]. Juvenile 
harp and hooded seals stranded on the US Atlantic coast in increased numbers from 1998 to the end of 
1999 (Figure 3). The event was again associated with circulating PDV [55] and may have precipitated 
the prolonged increase in multi-species mortality through the first decade of the century in the New 
England region (Figure 3). This latter unusual mortality event included the first cases of clinical disease 
and death associated with PDV in grey seals in North America [44,56] and the first isolation of a North 
American strain of PDV from a harbor seal from the US Atlantic coast [44]. The phylogenetic 
relationship between this isolate, isolates from the two European epidemics, and the harp seal PDV have 
yet to be established. Preliminary investigations suggest that mutations in the F and M genes of PDV 
USA 2006 isolated from brain tissues were not present in isolates from lung, liver, or blood suggesting 
possible virus persistence in the central nervous system [44]. Furthermore, PDV USA 2006 has only a 
few amino acid substitutions in the P, M and F genes compared to the 1988 European Ulster/Netherlands 
strain of PDV [41]. Thus, the 2006 isolate from the United States might have emerged independently 
from 2002 PDV strains and multiple lineages of PDV might be circulating among endemically infected 
seals in the northwestern Atlantic [44]. 
6.2.2. Eastern North Atlantic 
The epidemiology of PDV in the northeastern Atlantic has been very well studied [41,199–201], 
particularly following the two European outbreaks (Figure 4) [94,202], and the volume of detailed data 
collected during both the 1988 and the 2002 events has been crucial in facilitating our understanding of 
the determinants and dynamics of the infection [116,158,203,204]. In particular it has enabled various 
mathematical models to be constructed from which predictions about the occurrence and impact of future 
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events have been made [205–208]. The results of these different approaches have greatly enhanced our 
understanding of the modes and methods of disease transmission and the factors involved in determining 
the spread of the disease and the severity of the outbreaks. Most importantly detailed ecological and 
demographic data was collected from a very large proportion of beached carcasses or animals that died 
following admission into rehabilitation centers. This included the species, sex, age, condition and 
stranding location across all the European countries involved [174,201–203]. In addition, the occurrence 
of these two substantial outbreaks across largely the same geographical region, has allowed for a 
comparative approach [41,200]. Indeed some of the same researchers were involved in responding to 
and studying both epidemics which has increased the collective collaborative output as data were 
gathered using standardized protocols, similar techniques and approaches [202,209,210]. 
 
Figure 3. Pinniped strandings by species for the US Atlantic coast for the period 1988 to 
2014. The peaks in strandings in 1991/1992; 1998/1999, and from 2004 to the end of 2007 
were associated with confirmed PDV infection in harbor [54], harp and hooded seals [55], 
and grey seals [56].  
The initial cases of PDV in both outbreaks were identified in the Danish and Swedish Kattegat with 
the Danish island of Anholt being the breeding colony where the first cases were reported [3,116]. 
However, the reasons why this location is the starting point for the outbreaks remain elusive. An 
additional puzzling spatial feature was that the epidemics did not spread in a geographically coherent 
pattern. Whilst initially they spread linearly away from Anholt, new epicenters appeared as time 
progressed [41], suggesting vectors other than harbor seals (that generally forage coastally from  
haul-out sites) were responsible [41,200]. In the North Sea the grey seal, which was exposed but did not 
show overt infection or mortality [211] remains the most likely source. Indeed studies during the grey 
seal breeding season in the UK at the end of the 2002 epidemic found that blood samples from females 
and pups were PDV positive by PCR. Additionally, PCR positive pups with negative mothers were 
detected late in the breeding season suggesting transfer of virus across the colony [118]. However, 
whether grey seals are true reservoirs of infection or subclinical carriers is still to be determined [212]. 
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Figure 4. North polar azimuthal equidistant projection showing the location of 1988 and 
2002 PDV epidemics in the northeastern Atlantic (lower right black oval); two mortality 
events in the northwestern Atlantic in which PDV infection was confirmed (left black oval); 
putative PDV-associated Kuril seal mortalities, Hokkaido, Japan (upper right grey circle); 
and presumptive PDV mortality in northern sea otters in southern Alaska (upper left grey 
circle). Distribution ranges or harbor, grey, harp, ringed seals and sea otters are shown. 
The dynamics of infection differed regionally, particularly in Scotland where the prevalence of PDV 
antibodies was low following both outbreaks, more so in 2002 where the disease did not reach epidemic 
levels [200]. Lower mortality rates were also seen in England in 2002 compared to the European 
mainland and the earlier outbreak [202]. These region-specific patterns have therefore been important 
in improving our understanding of the factors regulating the severity of the outbreaks. Modeling the 
geographical spread of PDV and the utility of these models in the prediction of future events has been 
an active area of study, particularly since the 2002 outbreak. For example, spatially explicit modeling 
studies [213] used an individual-based model of seal movement, using tracking data obtained from 
harbor seals fitted with satellite relay data loggers, to combine realistic representations of animal 
behavior with traditional SEIR models [214]. It was concluded that the most important factors that affect 
the regional and temporal spread of infection are linked to the contact rate between infective and 
susceptible individuals, and that animal movement and haul-out connectivity are highly influential. 
Since life history stage will also affect activity as animals spend more time on land during breeding and 
molt [215], season is also a key factor. This approach could be expanded and enhanced in future to 
include the movements of grey seals as potential vectors or reservoirs of infection.  
Further comparative modeling studies combining antibody prevalence serology data with a simple 
SEIR model found some interesting differences between the two outbreaks in the UK [202]. Overall the 
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model suggested that there was a 27% (95% CI: 8% to 43%) fall in R0 the basic reproductive rate (i.e., 
the number of cases generated by an infected individual during the infectious period in an uninfected 
population and is a combination of transmissibility, contact and duration of infectiousness) of the virus 
between outbreaks. However, viral transmission characteristics were similar throughout the UK and R0 
was uniform within each epidemic. Thus the differences appear to have been mainly due to differences 
in case mortality. Seasonal differences in behavior resulting in more intense rather than more frequent 
contact between infectives and susceptibles may have resulted in differences in viral dose and the 
observed difference in case fatality rate. Higher mortality was seen in the fast growing European 
populations [216] where animals are not likely to be in poor condition, suggesting that other factors such 
as immunogenetic differences or immunotoxic effects of persistent organic pollutants may be at play [200]. 
The impact that an epidemic has on the future population dynamics of the species is determined not 
only by the overall mortality rate but also by the sex and age classes that are affected. Both epidemics 
had differential effects, particularly on the age classes that died [217]. Mortality among the young  
(<1 year) and older (>4 years) age classes was significantly higher than among the sub-adults, and males 
suffered significantly higher mortality than females. The study concluded that genetic susceptibility 
could not be the cause of this difference as adult mortality was higher than offspring mortality but that 
contact rate and susceptibility were likely to be strongly age and sex-specific. However, immunogenetic 
differences could explain the regional variation seen in mortality rates. For example, a study of MHC 
class I genes (which are critical for antigen presentation to T and NK cells), found presence/absence 
differences for some polymorphisms between UK harbor seal populations in southeast Scotland that 
were PDV survivors, and from southeast England that had died from the infection. However, the sample 
sizes were too small to draw firm conclusions [131]. This intriguing difference, and the variation 
identified by McCarthy et al. [65] for other immune-related genes, need to be investigated further. 
Nonetheless, life-long immunity to infection and the rate of acquired immunity development are key 
drivers of mortality patterns and spread of infection. The effect of acquired immunity on a simulated 
population of harbor seals subject to repeated PDV outbreaks was modeled and it was concluded that 
life-long immunity could actually impede the evolution of genetic disease resistance by maintaining 
susceptible genotypes in the population [205]. However, PDV mediated selection could still drive 
significant increases in resistance allele frequencies within a century, which would in turn buffer the 
impacts of future epizootics. 
The population level impact and the consequences of repeated PDV epidemics for the long-term 
population persistence is an essential consideration in the conservation and management of the harbor 
seal in European waters [218]. This question was addressed using a stochastic model to analyze the  
long-term impacts on population dynamics [219]. However, in a response to this work, Lonergan and 
Harwood [220] indicated that their initial analyses did not include immunity in individuals that had 
survived previous outbreaks. This had a critical impact on the quasi-extinction risk estimates for harbor 
seals in Europe, where the estimated inter-epidemic interval for PDV is around 14 years [219]. Once 
included, the risk of a population decline to 10% of an initial population of 50,000 over 100 years was 
about 0.05 and if all the survivors of previous events are immune this declined to less than 0.01. These 
scenarios were for rapidly growing populations such as is currently seen in the Wadden Sea [221,222] 
and extinction risk is understandably more serious for populations that are declining due to other factors, 
such as those in some regions of Scotland [223]. Of some note is that European populations have largely 
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recovered to their pre-2002 outbreak sizes, and although the recovery was delayed in some populations, 
particularly those in the Wash, SE England, they too are now increasing rapidly [224]. Consequently 
local population abundance, haul-out density, animal movement and the seasonal timing of any future 
outbreak could all affect contact rate. In addition, a recent study investigated the effect of maternal 
immunity on estimating the inter-epidemic interval for PDV in Europe [225]. Depending on the model 
assumptions, this could range from 6 to 12 years. Thus, risk predictions associated with repeated PDV 
outbreaks for declining populations remain challenging. 
6.2.3. North Pacific 
The western Arctic, Bering and Chukchi Seas, and North Pacific Ocean have large and diverse 
populations of potentially PDV-susceptible marine mammals and some species such as ringed seals and 
bearded seals have a continuous distribution from the eastern Canadian Arctic to Alaska. Furthermore, 
some of these species including the northern sea otter, Steller sea lion (Eumetopias jubatus), northern 
fur seal (Callorhinus ursinus) and harbor seal, have experienced population declines through part of 
their range [180,226]. Although the cause of these declines is likely multifactorial, the role of infectious 
diseases requires investigation [227]. In Canada the most westerly PDV seropositive ringed seals were 
sampled at Paulatuk, NWT, close to the Alaskan border, in 1993 [12]. Early sero-surveillance in Alaskan 
waters using a CDV neutralization test, found no evidence of infection in ringed seals, harbor seals (P. 
vitulia richardsi) spotted seals (Phoca largha), bearded seals (Erighnathus barbatus), ribbon seals 
(Histriophoca fasciata), Steller sea lions or Pacific walrus (O. rosmarus divergens) sampled in the 
Bering Sea between 1984 and 1988 [6]. Later re-testing of the same sera found low or equivocal PDV 
plaque reducing antibody titers in some animals (Duignan and Nielsen unpublished). 
Further south in Alaska, including the coasts of southeastern Alaska, Kodiak Island and Prince 
William Sound, harbor seals were sampled for serology between 1976 and 1999 [177]. While two of 
160 seals had low PDV neutralizing titers, these were assumed to be false positive reactions [177]. A 
survey of 165 Steller sea lions in the same geographic region sampled between 1998 and 2000 found 
only one pup with neutralizing antibodies against dolphin and porpoise morbillivirus, but not PDV or 
CDV, and was negative by a competitive ELISA assay [180]. The authors concluded that this too was 
probably a false positive reaction. In Boundary Bay, British Columbia, a sample of 21 harbor seals (14 
adult, 7 juvenile) were seronegative for all morbilliviruses [106]. Northern sea otters sampled in the 
western Aleutian Islands and at Elfin Cove in SE Alaska in 1997, and southern sea otters sampled in 
Monterey Bay, California, from 1995 to 2000 were all seronegative by ELISA [178]. 
The first compelling evidence for the presence of a morbillivirus in Pacific marine mammals was the 
discovery of 40% seropositivity in a PDV neutralizing test of live-captured sea otters from the Eastern 
Aleutian Islands sampled in 2004 and 2005 [117,181]. This stock of northern sea otters had declined 
dramatically from 74,000 to just under 9000 between the 1980s and 2000, and in 2006 large numbers of 
deaths were recorded in in south-central Alaska (Figure 3). However, although there was only equivocal 
evidence of morbillivirus pathology in examined animals, morbillivirus nucleic acid was amplified from 
10% of nasal swabs of healthy live-captured otters and from tissues (lung, lymph node or brain) of three 
of nine beached carcasses found between 2005 and 2008 [117]. Partial sequence analysis of the P gene 
showed identity with PDV from Europe 2002 and close alignment with PDV from Europe 1988 and 
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USA 2006 [44,117]. No sequence data was available for the more conserved and functionally significant 
H glycoprotein gene so speculation as to whether PDV arrived in Alaska along the Arctic Ocean 
coastline following the 1988 epidemic or one of the subsequent events is premature. More likely is the 
hypothesis that several lineages of PDV are circulating in endemically infected pinniped populations of 
the North Atlantic as occurs with CDV in terrestrial mammals [44,45]. If PDV has been present in the 
area since 2004, it is intriguing that there have been no confirmed PDV mortality events on the Alaskan 
coast. Northern sea otters are sympatric with PDV-naïve harbor seals in the Eastern Aleutian Islands and 
throughout the area of sea otter mortality in 2006. Further mortality surveillance of pinnipeds in this 
region is warranted.  
Northern sea otters also occur along the Pacific coast as far south as northern California. In 
Washington State a mortality event occurred between July and August 2000 but the etiology was never 
established [182]. Retrospective serology on otters sampled from 1992 to 1997 were negative in a PDV 
and CDV competitive ELISA [179]. However, otters sampled later in 2001 were 80% (24/30) positive 
to CDV in a neutralization test while 10% (3/30) were positive in 2011 [182]. Differential serology 
suggested that CDV was the pathogen but PCR testing of nasal swabs proved negative. The conclusion 
was that terrestrial origin CDV was the cause and a precedent for this was the CDV epidemics among 
Baikal and Caspian seals in Asia [1,228]. Further south on the US Pacific coast, there has been no 
evidence for morbillivirus infection in pinnipeds or sea otters [179]. 
Marine mammal disease surveillance is more sporadic in the western North Pacific. A serologic 
survey was conducted on Kuril harbor seals (P. vitulina stejnegeri) at three locations on the southeastern 
coast of Hokkaido, Japan, between 1998 and 2005 [183]. Using an ELISA with PDV or CDV antigen, 
it was shown that at Nosappu, seals were PDV-seropositive in 1998 (50%), 2003 (5%), 2004 (1%) and 
2005 (1%). A similar pattern was observed further south at Erimo where the prevalences were 13% 
(1999), 7% (2003), 50% (2004) and 0% (2005). Sixteen seals sampled at Akkeshi, between the previous 
two sites, were negative in 2004 and 2005. The authors discussed another report in Japanese [184] in 
which 19/23 (83%) of Kuril harbor seals from Hokkaido sampled in 1996 and 2/2 sampled in 1997 were 
PDV seropositive. Furthermore, greater than 50% of an unspecified number of Steller sea lions and 
spotted seals sampled between 1994 and 1998 tested positive. While no data are provided on stranding 
rates, mortalities or other diagnostic tests, the authors postulate that epidemics may have occurred around 
Hokkaido (Figure 3) prior to 1998 and again around 2004 [183]. Further research effort is certainly 
required to obtain a clearer understanding of morbillivirus epidemiology in this region. 
6.2.4. Southern Oceans 
To date there is very little conclusive evidence for PDV in southern hemisphere pinnipeds. Antarctic 
crabeater (Lobodon carcinophagus) and leopard seals (Hydrurga leptonyx), but not Weddell seals 
(Leptonychotes weddellii) showed serological evidence of CDV exposure but there have been no 
confirmed mortalities [188]. Infection was likely introduced to Antarctica with expedition sled dogs. A 
serological survey of a small number of Weddell seals, Ross seals (Ommatophoca rossii, and crabeater 
seals from the pack-ice off Queen Maud Land, Antarctica sampled in 2001 showed no detectable PDV 
antibody levels [111]. In the New Zealand sub-Antarctic islands, a number of sea lions (Phocarctos 
hookeri) and New Zealand fur seals (Arctocephalus forsteri) had PDV neutralizing titers but there was 
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no evidence of disease [185]. Titers in adult female New Zealand sea lions that died from a 
Campylobacter spp. septicemia epidemic in 1998 were too low to implicate PDV in the deaths and there 
were no morbillivirus lesions in tissues [186]. In Australia, a serological survey was conducted on 125 
adult female Australian fur seals (A. pusillus doriferus) sampled at Kanowna Island rookery in Bass 
Strait between 2007 and 2009 [187]. A VeroDogSLAM plaque reduction assay for CDV was used but 
all animals were negative [187]. 
7. Conclusions and Future Directions  
Since the discovery of PDV in 1988, it has become the most ecologically significant pathogen of 
pinnipeds, certainly in the northern hemisphere. At the First International Symposium on Morbillivirus 
Infections in Hannover, 1994, a workshop was convened to discuss the current understanding on the 
new marine mammal pathogens in the morbillivirus genus [15]. In retrospect, our knowledge at that time 
was quite limited. We understood the basic pathology and serology because of the similarities with CDV, 
could determine antigenic and genetic relationships to create rudimentary phylogenetic trees, and were 
beginning to grasp the intricacies of PDV epidemiology. Twenty years later, this review is testament to 
a huge corpus of research that has been generated largely because of the continued high profile of PDV 
as an agent of mass mortality for European harbor seals and smaller die-offs in eastern North America, 
and the recent emergence of infection in the North Pacific. The Princeton RAPIDD workshop was 
convened at this juncture to capture the advances in disparate fields of research pertinent to this deadly 
infection, to identify significant knowledge gaps, and to harness and channel the expertise of the 
assembled scientists into coordinated investigations on viral pathogenesis, immune response, 
phylogenetics, ecology and population dynamics.  
Significant advances in understanding the pathogenesis of PDV have been made by the discovery of 
specific host cell receptors (CD150 and PVRL 4) that determine tissue (lymphoreticular cells, epithelial 
cells) and host specificity. Vero cells expressing canine CD150 receptor have since been developed to 
enhance our capacity to isolate wild-type PDV from field cases and as reagents for serology tests. 
However, we continue to speculate on the mode of entry of PDV into cells of the central nervous system. 
Does the virus persist in the protected environment of the brain and even acquire strain differences as 
has been suggested by some research findings? What determines host specificity and why are some 
species so susceptible to infection while others appear resistant to clinical disease? Could there be 
qualitative and quantitative differences in the distribution and affinity of relevant receptors? Answers to 
some of these questions may be provided by study of seals affected by field infection to assess the 
distribution of virus in tissues of different species infected by known viral strains. However, 
understanding of the molecular mechanisms will probably require development of in vitro models to 
assess attachment, infectivity and replication of the virus in specific cell types. Such studies will provide 
a greater insight on pathogenicity but will also facilitate the development of more sophisticated vaccines 
or therapeutics for endangered species such as the monk seals discussed in this review.  
Considerable advances have been made in understanding the immune response of pinnipeds to PDV 
field infection and to vaccination by various attenuated and subunit vaccines as reviewed. Although we 
are closer to deployment of an inactivated vaccine as a strategy to protect the potentially vulnerable 
Hawaiian monk seal, further work is required to model the efficacy of such an approach. Better 
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characterization of the immune response of different species of pinniped cells to different variants of 
PDV is required using in vitro approaches, and animal models to tease apart the genetic determinants, 
role of cytokines in immune response and immunosuppression (Th1 versus Th2 responses), and the 
components of cellular and humoral immunity.  
Advances in molecular biology in the past 20 years have greatly enhanced our capacity to extract and 
sequence the morbillivirus genome reducing sequencing errors and the effects of adaptation to cell 
cultures. Complete sequences for the major genes are available for PDV from both European epidemics 
and from the USA 2006 mortality event affecting harbor seals. These will facilitate the resolution of the 
phylogenetic classification of PDV and its relationship with other members of the genus. However, 
similar sequence data are not available for other potential host species and are particularly lacking (apart 
from partial P gene sequence) for the harp seal. As this species is still the best candidate for reservoir of 
infection in the greater North Atlantic ecosystem, isolation of the virus and mapping the genome of PDV 
from harp seals should enable a better understanding of the spatial and temporal dynamics of infection. 
Similarly, more complete genetic mapping of the northern sea otter PDV genome is needed to determine 
the origin of this virus and its relationship to the North Atlantic variants.  
The two major epidemics in Europe provided an unprecedented opportunity to develop various 
mathematical models from which predictions about the recurrence and impact of future events. In 
particular, the distribution of the outbreaks across largely the same geographical region, has allowed for 
a comparative approach with collaborative teams in several countries teasing apart the effects of time, 
space and seal ecology on disease transmission and expression. The use of individual-based models of 
seal movement from satellite tracked animals enabled researchers to combine realistic representations 
of animal behavior with traditional SEIR models and show how contact rate, animal movement, and 
haul-out connectivity are highly influential in epidemic dynamics. Significant knowledge gaps still exist 
for the northeast Atlantic and not least is where does PDV reside in the inter-epidemic interval? Does 
the more disease resistant grey seal play a role as vector around the coasts of Europe? What role does 
the eastern harp seal population play? What are the determinants of case fatality rate in harbor seals 
across metapopulations? How do immunogenetics and immunotoxicology impact the epidemiology? 
Developments in genomic technology now allow us to take a population genomic approach to assess 
genetic contributions to intra and interspecies differences in PDV susceptibility, building on the earlier 
studies of neutral markers and candidate genes. 
In the western North Atlantic PDV appears to have been endemic in the larger and more diverse 
populations of pinnipeds for quite some time. While harbor and grey seals are found on both sides of the 
Atlantic, a key difference is the very large harp seal population that is seasonally resident on the sea ice 
of Maritime Canada and in close proximity to both grey and harbor seals. A second significant difference 
between east and west is that grey seals in UK waters, where the largest European population resides, 
breed in November, well before harbor seal breeding season in early summer. Therefore by the time the 
PDV epidemics started in Europe in April or May, the grey seal juveniles were already six months old 
and probably less vulnerable to infection. By contrast, in Canada and Maine, grey seal pups are born in 
February, harp and hooded seals in March, and harbor seals from April through early summer. Thus 
although there is high herd immunity in harp and gray seals, and moderate in hooded and harbor seals, 
there is an enormous influx of susceptible animals into the ecosystem each spring/summer. In this 
scenario, PDV has the potential to cause repeated but limited mortality events that can involve multiple 
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species, mostly juveniles, but also older susceptibles for species like the harbor seal with lower herd 
immunity. While pinniped populations are higher in Atlantic Canada and the USA, large-scale epidemics 
as occur in Europe are never likely to occur because of the level of herd immunity. While this much we 
know, there is much more to understand about the dynamics of viral transmission and maintenance in 
this complex multi-host ecosystem.  
Perhaps the greatest unknown to emerge from the RAPIDD workshop is the status of morbillivirus 
infection in the North Pacific. A PDV-like virus appears to have crept silently into central Alaska in the 
early 2000s and may or may not have been associated with a mortality event in northern sea otters in 
2006. Preliminary data suggest that infection, based on serology and PCR, may now also be widespread 
in pinnipeds in the region. Given the propensity for PDV to cause epidemics in naïve phocid populations, 
the apparent lack of mortality among potentially vulnerable sympatric Pacific harbor seals is difficult to 
explain. Partial sequence data on the sea otter morbillivirus P gene indicates similarity to PDV from the 
North Atlantic; however, virus isolation and substantially more sequence data are required before the 
phylogenetic relationships can be determined. Equally intriguing is whether or not this virus or yet 
another variant is circulating in the coastal waters of Japan and Russia and possibly causing localized 
epidemics among Kuril harbor seals. Further surveillance in the North Pacific in general is required 
before we can speculate on the ecology of PDV in this region. 
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